View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Kering: Half yearly achievement report on Kering share quotations liqu...

Kering: Half yearly achievement report on Kering share quotations liquidity mandate - June 2025 PRESS RELEASEJuly 4, 2025 HALF-YEARLY ACHIEVEMENT REPORT ON KERING SHAREQUOTATIONS LIQUIDITY MANDATE Pursuant to the liquidity mandate granted by Kering to Rothschild Martin Maurel, the following assets appeared on the liquidity account as of June 30th, 2025: 240 shares€26,395,783 Number of executions on buy side during the semester: 15,526 Number of executions on sell side during the semester: 16,774 Traded volume on buy side during the semester: 380,540 shares for €79,648,592.58 Traded ...

 PRESS RELEASE

Kering : Bilan semestriel contrat de liquidité Juin 2025

Kering : Bilan semestriel contrat de liquidité Juin 2025 COMMUNIQUÉ DE PRESSE4 juillet 2025 COMMUNIQUE ETABLISSANT LE BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE DE LA SOCIETE KERING Au titre du contrat de liquidité confié par la société Kering à Rothschild Martin Maurel, à la date du 30 juin 2025, les moyens suivants figuraient au compte de liquidité : 240 titres26 395 783 € Nombre de transactions exécutées sur le semestre à l'achat : 15 526 Nombre de transactions exécutées sur le semestre à la vente : 16 774 Volume échangé sur le semestre à l'achat : 380 540 actions pour 79 648 592,58...

Carole Braudeau
  • Carole Braudeau

Credit Morning 07/04/2025

While the offer on Mediobanca will open on July 14, Monte has set a minimum threshold of 35%.|

Carole Braudeau
  • Carole Braudeau

Morning Crédit 04/07/2025

Alors que l’offre sur Mediobanca ouvrira le 14/07, Monte fixe un minimum threshold à 35%.|

Eutelsat Communications S.A.: 1 director

A director at Eutelsat Communications S.A. sold 64,586,426 shares at 4.000EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last ...

Delphine Brault ... (+2)
  • Delphine Brault
  • Steven Boumans
Delphine Brault ... (+2)
  • Delphine Brault
  • Steven Boumans
Michael B. Schäfer ... (+2)
  • Michael B. Schäfer
  • Stephan Wulf
Research Department
  • Research Department

INFORME DIARIO 30 JUNIO (ANÁLISIS BANCO SABADELL)

COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: IBERDROLA, REDEIA. EUROPA: KERING Menores riesgos comerciales y geopolíticosSemana de ganancias en los índices europeos, apoyados por el alto al fuego entre Israel e Irán y las expectativas de acuerdo comercial con EE.UU. Así, en el STOXX 600 los mejores sectores de la semana fueron Construcción y Viajes&Ocio mientras que Alimentación y Energía terminaron con las mayores caídas. Por el lado macro, en la Eurozona el índice de confianza económica de ju...

Carole Braudeau
  • Carole Braudeau

Credit Morning 06/26/2025

Vilmorin & Cie has entered into exclusive discussions to build a strategic and financial partnership with ADQ on Vegetable Seeds|Finnair: more industrial actions announced|

Carole Braudeau
  • Carole Braudeau

Morning Crédit 26/06/2025

Vilmorin & Cie en discussions exclusives avec ADQ pour établir un partenariat stratégique et financier sur les Semences Potagères|Finnair: more industrial actions announced|

 PRESS RELEASE

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN...

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE Vazkepa® supported by strong clinical data package and expected to contribute to Specialty & Primary Care growth in coming years Milan, 24 June 2025 – Recordati today announced a licensing and supply agreement with Amarin to commercialize the marketed cardiovascular medicine, Vazkepa® (icosapent ethyl) across 59 countries, focused in Europe. Vazkepa® is indicated to reduce the r...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch